Can empagliflozin (Jardiance) cause bilateral leg sores?

Can Jardiance Cause Bilateral Leg Sores?

Jardiance (empagliflozin) does not directly cause typical leg sores, but it is associated with serious lower extremity complications that can present as skin lesions, particularly necrotizing fasciitis of the perineum (Fournier's gangrene) and, in rare cases, cutaneous vasculitis. The FDA label explicitly warns about necrotizing infections requiring urgent surgical intervention 1.

Direct Skin/Soft Tissue Complications

Necrotizing Fasciitis (Fournier's Gangrene) is the most serious skin-related adverse effect:

• Presents with pain, tenderness, erythema, or swelling in the genital or perineal area, often with fever or malaise 1
• Can extend to the legs and requires immediate discontinuation of Jardiance, broad-spectrum antibiotics, and surgical debridement
• Reported in both males and females, with serious outcomes including hospitalization, multiple surgeries, and death 1

Cutaneous Vasculitis has been documented in at least one case report:

• A 69-year-old man developed tender subcutaneous nodules on his legs after starting empagliflozin, diagnosed as cutaneous polyarteritis nodosa (medium-vessel vasculitis) 2
• Complete resolution occurred after medication cessation
• This represents a rare but documented drug-induced cutaneous reaction

Indirect Lower Extremity Complications

The relationship between SGLT2 inhibitors and lower limb problems is complex and class-dependent:

Amputation Risk - Drug-Specific Differences:

• Canagliflozin showed increased amputation risk in CANVAS trial (6.3 vs 3.4 per 1,000 patient-years; HR 1.97) 3, 4
• Empagliflozin (Jardiance) demonstrated superior limb survival in PAD patients compared to placebo in EMPA-REG OUTCOME subgroup analysis 3
• The FDA removed the black box warning for canagliflozin in August 2020 after conflicting subsequent data 3

Mechanism of Lower Extremity Ulceration:

• SGLT2 inhibitors can cause volume depletion and hypotension, potentially compromising peripheral perfusion 1
• Patients with pre-existing peripheral arterial disease, severe neuropathy, or diabetic foot ulcers are at higher baseline risk 5, 6
• Genital mycotic infections (common with Jardiance) can theoretically extend or complicate adjacent skin 1

Clinical Evaluation Algorithm

When a patient on Jardiance presents with bilateral leg sores, assess:

1. Location and characteristics:

   • Perineal/genital involvement with systemic symptoms → suspect necrotizing fasciitis (medical emergency)
   • Subcutaneous nodules with tenderness → consider drug-induced vasculitis
   • Distal foot/toe ulcers → evaluate for diabetic foot disease or PAD

2. Risk factors present:

   • Pre-existing PAD, peripheral neuropathy, or prior amputation 5, 6
   • Recent volume depletion, hypotension, or acute kidney injury 1
   • History of recurrent skin/soft tissue infections

3. Temporal relationship:

   • Onset within weeks to months of starting Jardiance suggests drug causation
   • Pre-existing ulcers may represent underlying diabetic complications rather than drug effect

Management Recommendations

If necrotizing fasciitis suspected:

• Immediately discontinue Jardiance
• Start broad-spectrum antibiotics and arrange urgent surgical consultation 1
• Provide alternative glycemic control

If drug-induced vasculitis suspected:

• Discontinue Jardiance and observe for resolution 2
• Consider dermatology consultation and skin biopsy if diagnosis unclear

If typical diabetic foot ulcers:

• Continue Jardiance if cardiovascular/renal benefits outweigh risks (empagliflozin specifically showed limb protection in PAD patients) 3
• Optimize wound care, offloading, and vascular assessment
• Monitor closely for infection or progression

Important Caveats

The 2024 ACC/AHA PAD guidelines specifically recommend SGLT2 inhibitors with proven cardiovascular benefit (including empagliflozin) for patients with PAD and type 2 diabetes, noting that empagliflozin does not increase amputation risk 3. The 2024 ESC guidelines similarly support SGLT2 inhibitor use in PAD, with caution primarily for canagliflozin 7.

Common pitfall: Attributing all lower extremity lesions in diabetic patients to medication rather than recognizing underlying diabetic foot disease, PAD, or neuropathy. Jardiance itself rarely causes leg sores, but serious infections like Fournier's gangrene require immediate recognition and action.